Each endogenous opioid peptide stimulates the stress hormone corticosterone through its own preferred receptor — and tolerance develops at the specific receptor level.
Receptor-specific toleranceCross-tolerance studies proved each peptide acts through its own receptor
What the researchers found
All four tested opioid peptides (beta-endorphin, dynorphin, MEAP, and DADLE) increased plasma corticosterone (a stress hormone) in normal rats. The effects were dose-dependent and blocked by naloxone, confirming they work through opioid receptors.
Cross-tolerance experiments revealed which receptor each peptide uses. Rats made tolerant to one opioid were tested with others. Dynorphin(1-13) and MEAP (Met-Enk-Arg-Phe) acted at kappa-opioid receptors. The synthetic peptide DADLE acted at delta-opioid receptors.
Beta-endorphin was the surprise. It did not fit neatly into the mu, delta, or kappa categories. Its corticosterone-releasing effect was maintained even in rats tolerant to all three receptor types. The researchers proposed it acts at an epsilon-opioid receptor, a debated fourth receptor type.
Why it matters
This study provided in vivo evidence that the brain has multiple independent opioid systems controlling stress hormones. Each endogenous opioid peptide has its own preferred receptor. This means the stress response is not controlled by a single switch but by multiple parallel circuits.
How the study worked
Rats were made tolerant to specific opioid drugs: morphine (mu), U50488H (kappa), DADLE/morphine (delta), or beta-endorphin. Each tolerant group was then tested with the other opioid peptides. Corticosterone levels measured the functional response. All peptides were given by intracerebroventricular injection (directly into the brain). This is an animal study, not tested in people.
What this study cannot tell us
Tested in rats, not people. Intracerebral injection bypasses normal delivery routes. The epsilon receptor concept remains controversial and has not been definitively proven. Cross-tolerance is an indirect way to determine receptor specificity.
How to read the evidence
Preliminary animal study with elegant cross-tolerance design, but findings not confirmed in humans.
When this study was published
Published in 1987 — early systematic characterization of in-vivo receptor specificity.
The bigger picture
Understanding receptor-specific tolerance helps explain why rotating between different types of pain medications can maintain effectiveness, and why opioid peptide systems do not become uniformly desensitized.
Questions still open
- Can receptor-specific tolerance be exploited therapeutically?
- Do humans show the same receptor-specific tolerance patterns?
Common questions
What is opioid tolerance?
What are kappa, mu, and delta receptors?
Read the original research
Mu-, delta-, kappa- and epsilon-opioid receptor modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis: subchronic tolerance studies of endogenous opioid peptides.
Brain research, 435(1-2), 220-6
Citation
Iyengar, S; Kim, H S; Wood, P L. (1987). Mu-, delta-, kappa- and epsilon-opioid receptor modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis: subchronic tolerance studies of endogenous opioid peptides.. Brain research, 435(1-2), 220-6.